Subscribe Sign In Register

Premium

OrbiMed gains on Amarin’s hearty rally

Amarin’s latest clinical test results suggest that the drug is on track to win Food and Drug Administration approval this year.

April 30, 2011
75pete-gallo.jpg

By Pete Gallo

null

null

Sam Isaly’s biotech and pharma hedge fund looks to have a winner on its hands.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Amr101 Orbimed Amarin Sam Isaly
Related
Car in the middle of a road with cars parked on either side, Scotland, UK
Premium
Top Performer Sosin Partners Braces for Possible Roadblock
Stephen Taub
February 20, 2025
Beautiful lying Sumatran tigress
Premium
Top Hedge Funds Bet Big: D1, Lone Pine, Maverick, Viking Make Major Moves
Steve Taub
February 18, 2025
Aerial view of tractor as dragging a sowing machine over agricultural field, farmland
Sponsored
After a Mixed 2024 for U.S. Agriculture, What’s Next?